Firms Must Submit The Good, Bad, And Ugly Trial Data On Devices Under Clinical Trials Rule
Executive Summary
Device firms will have to submit a lot more clinical trials outcomes data to the ClinicalTrials.gov portal – including for products that have not been cleared, approved, or launched – based on a final rule recently issued by HHS. Even though sponsors can delay reporting two years, the rule expands the volume of reports that will find their way to the public-facing, clinical trials website, and the change could have downsides, attorneys say.
You may also be interested in...
HHS ClinicalTrials.Gov Rule Details Penalties For Failure To Submit
The US department's final rule for disclosing summary results to clinical trials extends to early studies of unapproved products.
FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks
In a draft guidance, FDA explains how it plans to communicate signs of postmarket device risks before it has performed a full analysis or developed specific recommendations. Public health advocates say it is a positive move to get ahead of potential safety problems early. The agency is seeking comment from companies on whether it needs to consult with firms prior to releasing information on emerging signals about their devices.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.